Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study.

Marzo-Ortega, H.; Sewerin, P.; Selmi, C.; Russ, H.; Ng, KJ.; Ngantcha, M.; Gerwien, JG.; Kennedy, D.; Gallego-Flores, A.; de la Torre, I.; Gladman, DD.; Coates, LC.

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study.

All Authors

Marzo-Ortega, H.

Sewerin, P.

Selmi, C.

Russ, H.

Ng, KJ.

Ngantcha, M.

Gerwien, JG.

Kennedy, D.

Gallego-Flores, A.

de la Torre, I.

Show 2 more

LTHT Author

Marzo-Ortega, Helena

LTHT Department

NIHR Leeds Biomedical Research Centre
Rheumatology

Publication Date

2026

Item Type

Journal Article
Observational Study
Comparative Study
Multicenter Study

Subject

ARTHRITIS, PSORIATIC , BIOLOGICAL PRODUCTS , ANTIRHEUMATIC AGENTS , HOSPITALISATION , MEN , WOMEN , MIDDLE AGED , ANTIBODIES, MONOCLONAL , TREATMENT OUTCOME , ADULT , AGED

Abstract

OBJECTIVES: This prespecified interim analysis of the PRO-SPIRIT observational study compares the effectiveness and persistence of ixekizumab (IXE) with other biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) among patients with psoriatic arthritis (PsA) after 12 months of real-world treatment. METHODS: Data were collected from a multinational cohort (n=1192) initiating IXE or other b/tsDMARDs. Comparative effectiveness between IXE and other b/tsDMARDs was assessed using frequentist model averaging, with multiple imputation for missing data. Pairwise comparisons were performed between IXE and tumour necrosis factor inhibitors (TNFi), secukinumab (SEC), Janus kinase inhibitors and pooled interleukin (IL)-12/23i & IL-23i groups. RESULTS: At month 12, IXE-treated patients displayed improvement in clinical Disease Activity in PsA index (cDAPSA) and body surface area (BSA) and the highest remission rate (cDAPSA score<=4; 18.8%). Versus pooled IL-12/23i and IL-23i, IXE patients were more likely to achieve cDAPSA remission (OR 2.0 (95% CI 1.2 to 6.0)) or very low disease activity (VLDA; OR 2.5 (1.1 to 13.6)), with greater pain reduction (least squares mean (LSM) (95% CI) -7.3 (-13.2 to -0.7)). Compared with TNFi, IXE patients exhibited greater BSA improvement (LSM (95% CI) -0.9 (-1.4 to -0.1)). IXE and SEC results were similar; most SEC patients received the 300 mg dose. Persistence rates were similar across groups, with varying reasons for discontinuation. CONCLUSIONS: IXE patients had significantly greater odds of achieving cDAPSA remission and VLDA, plus greater pain reduction versus the pooled IL-12/23i and IL-23i group, with significant improvements in BSA versus TNFi. Treatment persistence was similar among all b/tsDMARDs.